---
title: "KWAN ON HLDGS offers a 2-for-1 rights issue at HKD 0.07 per share, raising up to HKD 65.42 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273711531.md"
description: "KWAN ON HLDGS announced a proposed rights issue to issue up to 934 million shares; the subscription price is HKD 0.07, a discount of 17.65% compared to today's (26th) closing price. The maximum fundraising amount is HKD 65.42 million, with a net amount of HKD 63.62 million, of which 70.7% is intended for repaying the group's debts; 15.7% for developing existing businesses; and the remainder allocated for general working capital"
datetime: "2026-01-26T13:54:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273711531.md)
  - [en](https://longbridge.com/en/news/273711531.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273711531.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273711531.md) | [繁體中文](https://longbridge.com/zh-HK/news/273711531.md)


# KWAN ON HLDGS offers a 2-for-1 rights issue at HKD 0.07 per share, raising up to HKD 65.42 million

KWAN ON HLDGS (01559.HK) announced a proposed rights issue to issue up to 934 million shares; the subscription price is HKD 0.07, a discount of 17.65% compared to today's (26th) closing price. The maximum fundraising amount is HKD 65.42 million, with a net amount of HKD 63.62 million, of which 70.7% is intended for repaying the group's debts; 15.7% for developing existing businesses; and the remainder for general working capital

### Related Stocks

- [KWAN ON HLDGS (01559.HK)](https://longbridge.com/en/quote/01559.HK.md)

## Related News & Research

- [Kwan On Plans HK$65 Million Non-Underwritten Rights Issue to Cut Debt and Fund Projects](https://longbridge.com/en/news/273708119.md)
- [Kwan On Holdings Sets Out Board and Committee Structure](https://longbridge.com/en/news/273683803.md)
- [Guan Chao's Loss Balloons in 2025](https://longbridge.com/en/news/281314987.md)
- [Zhongtai Securities Sticks to Its Buy Rating for Wasion Holdings Limited (3393)](https://longbridge.com/en/news/281141455.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/en/news/281325910.md)